Producer
Nipro Corporation
Japanese diversified medical device and pharmaceutical packaging company (TYO: 8086; ~¥500B revenue); headquartered in Osaka. Nipro is the largest pharmaceutical glass vial manufacturer in Japan and a major global supplier, holding an estimated 10-15% of global pharmaceutical glass vial market share. Nipro's pharma glass operations span borosilicate vial production (Nipro Pharma Corporation subsidiary) and medical device manufacturing. Nipro is one of the few manufacturers with both pharmaceutical glass tubing drawing capability AND vial conversion capacity in-house — a vertical integration comparable to SCHOTT Pharma. Major supplier to Japanese domestic pharmaceutical manufacturers; growing export market in Asia, India, and emerging markets. Also the world's largest manufacturer of hemodialysis equipment and supplies.
2
Inputs supplied
2
Goods downstream
3
Facilities
1
Stories
What they make
2 inputs Nipro Corporation supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Nipro Corporation makes — pick one to see the full supply chain.
Where they make it
3 facilities
Nipro Corporation Odate Factory →
JPmanufacturing
Primary global production site for Nipro CTA dialyzers. Located in Odate, Akita Prefecture, northern Japan. Entirely dependent on Toyobo Iwakuni as sole-source CTA hollow fiber supplier. Both critical facilities are in Japan.
Nipro Osaka Main Manufacturing Complex →
JPOsaka, Japan · glass_tubing_and_vials
Headquarters manufacturing site. One of 13 global facilities. Produces borosilicate tubing in-house for vertical integration.
Nipro Pharma Corporation Osaka Vial Plant →
JPOsaka Prefecture · manufacturing
Nipro Pharma Corporation (Nipro subsidiary) pharmaceutical glass vial production in Osaka Prefecture, Japan. Primary site for Nipro's Japanese pharmaceutical glass vial output; serves both domestic Japanese pharmaceutical market and export markets. Nipro Pharma produces Type I borosilicate vials conforming to USP and JP (Japanese Pharmacopoeia) standards. Nipro is the largest pharmaceutical glass vial manufacturer in Japan and holds dominant share of the Japanese domestic parenteral packaging market. Source: https://www.nipropharma.co.jp/english/
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Pharmaceutical Glass (Vials + Syringes)
35%Dialysis Equipment + Supplies (World #1)
40%Medical Devices + CDMO
25%
Stories from the supply chain
Editorial about Nipro Corporation
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Nipro Corporation is simultaneously the largest pharmaceutical glass vial manufacturer in Japan and the largest hemodialysis (kidney dialysis) equipment and consumables manufacturer in the world. Nipro's dialysis division produces dialyzers (artificial kidney membranes), dialysis machines, and bloodlines used in renal replacement therapy for approximately 4 million dialysis patients globally. The pharmaceutical glass vials and the dialysis membranes are manufactured in entirely separate divisions using entirely different technologies — one is glass-blowing from borosilicate tubing, the other is hollow-fiber polymer membrane extrusion — and share only the parent company's Japanese corporate structure and quality management culture. A supply chain disruption at Nipro could simultaneously affect injectable drug packaging for Japanese pharmaceutical manufacturers AND dialysis consumable supply for kidney failure patients globally. This dual criticality in two completely different and unrelated life-sustaining applications is extremely rare for a single mid-sized industrial company.
Nipro Corporation ↗Capacity2022
Nipro Corporation invested approximately ¥100 billion ($1 billion) to double its artificial kidney (dialyzer) production capacity. This expansion, including the joint Odate CTA plant with Toyobo, was driven by a 7% annual growth rate in global hemodialysis patients. Nipro is the world's largest CTA dialyzer manufacturer and is entirely dependent on Toyobo Iwakuni (now + Odate) for its CTA hollow fiber supply. The $1B investment represents one of the largest single capital commitments by a Japanese medical device company to dialysis capacity expansion.
Nipro Asia ↗Origin2023
Nipro Corporation was founded in 1954 in Osaka as a glass tube manufacturer — one of many postwar Japanese companies that started in precision glass products and evolved into broader markets. Nipro's evolution from glass tube manufacturing to dialysis equipment followed the same logic as other Japanese precision manufacturers: the skills required to draw and process thin-walled glass tubes (dimensional control, surface quality, chemical purity) directly transferred to hollow fiber membrane manufacturing for dialysis. Hemodialysis membranes in the 1960s-1970s were initially made from modified cellulose (like Nipro's cellulose triacetate fibers) — a natural extension of glass fiber technology. Nipro became the world's largest hemodialysis equipment manufacturer by unit volume through a strategy of cost-competitive products targeting emerging market health systems (India, Southeast Asia, Middle East) where price sensitivity is high and dialysis infrastructure is expanding. The same Osaka company that started making glass tubes now keeps over 2 million kidney failure patients alive globally through its dialysis equipment — and packages the injectable drugs administered to those same patients in its pharmaceutical glass vials.
Nipro Corporation ↗